Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside.
Houghton
A N
AN
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Bajorin
D F
DF
Lonberg
M
M
Chapman
P
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D005732:Gangliosides / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000276:immunology; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D008545:Melanoma / Q000556:secondary* / Q000628:therapy; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D005732:Gangliosides; D007074:Immunoglobulin G; D007130:Immunoglobulin Idiotypes; C026226:ganglioside, GD3